NCT03224598View on ClinicalTrials.gov

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions
Dermatosis Papulosa Nigra
Interventions
DRUG

A-101 Topical Solution 40%

A-101 Topical Solution 40%

Trial Locations (2)

10155

Aclaris Investigational Site, New York

20037

Aclaris Investigational Site, Washington D.C.

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY

NCT03224598 - A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra | Biotech Hunter | Biotech Hunter